DOP2024000050A - Sales agonistas de sstr4 - Google Patents
Sales agonistas de sstr4Info
- Publication number
- DOP2024000050A DOP2024000050A DO2024000050A DO2024000050A DOP2024000050A DO P2024000050 A DOP2024000050 A DO P2024000050A DO 2024000050 A DO2024000050 A DO 2024000050A DO 2024000050 A DO2024000050 A DO 2024000050A DO P2024000050 A DOP2024000050 A DO P2024000050A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- salts
- sstr4
- sstr4 agonist
- agonist salts
- azabicyclo
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 5
- 102100023801 Somatostatin receptor type 4 Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 108010064556 somatostatin receptor subtype-4 Proteins 0.000 title 1
- -1 3-methyl-2-pyridyl Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a sales específicas de (1S,5R)-(1a,5a,6a)-N-[1,1-dimetil-2-[(3-metil-2-piridil)oxi]etil]-3-azabiciclo[3.1.0]hexano-6-carboxamida, a composiciones farmacéuticas que comprenden dichas sales, a métodos de uso de dichas sales para tratar trastornos fisiológicos, y a intermedios útiles en la síntesis de las sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163243785P | 2021-09-14 | 2021-09-14 | |
| PCT/US2022/076401 WO2023044326A1 (en) | 2021-09-14 | 2022-09-14 | Sstr4 agonist salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2024000050A true DOP2024000050A (es) | 2024-04-30 |
Family
ID=83508479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2024000050A DOP2024000050A (es) | 2021-09-14 | 2024-03-14 | Sales agonistas de sstr4 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11834435B2 (es) |
| KR (1) | KR20240056751A (es) |
| CN (1) | CN117940413A (es) |
| AR (1) | AR127055A1 (es) |
| AU (1) | AU2022348561A1 (es) |
| CA (1) | CA3231451A1 (es) |
| CO (1) | CO2024003038A2 (es) |
| DO (1) | DOP2024000050A (es) |
| IL (1) | IL311251A (es) |
| PE (1) | PE20240885A1 (es) |
| TW (2) | TWI822326B (es) |
| WO (1) | WO2023044326A1 (es) |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159941A (en) | 1996-05-14 | 2000-12-12 | Novo Nordisk A/S | Use of somatostatin agonists and antagonists for treating diseases related to the eye |
| US6355613B1 (en) | 1996-07-31 | 2002-03-12 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US6063796A (en) | 1997-04-04 | 2000-05-16 | Merck & Co., Inc. | Somatostatin agonists |
| US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| WO2004050024A2 (en) | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| US20100004339A1 (en) | 2003-10-06 | 2010-01-07 | Oy Juvantia Pharma Ltd. | Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists |
| FI20031454A0 (fi) | 2003-10-06 | 2003-10-06 | Juvantia Pharma Ltd Oy | Selektiivisiä somatostatiinireseptori 1 ja/tai 4 -agonisteja ja -antagonisteja |
| AU2004281794B2 (en) | 2003-10-14 | 2010-04-22 | Pfizer Products Inc. | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
| EP1931633A2 (en) | 2005-09-05 | 2008-06-18 | Ranbaxy Laboratories Limited | Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors |
| GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
| JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用 |
| CA2729767A1 (en) | 2008-07-07 | 2010-01-14 | Fasgen, Inc. | Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same |
| WO2010059922A1 (en) | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
| US8835472B2 (en) | 2010-09-02 | 2014-09-16 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
| WO2012042539A2 (en) | 2010-09-28 | 2012-04-05 | Panacea Biotec Ltd | Novel bicyclic compounds |
| EP2685828A4 (en) | 2011-03-17 | 2014-08-13 | Merck Sharp & Dohme | SUBSTITUTED 3-AZABICYCLO [3,1,0-] HEXAN DERIVATIVES AS CCR2 ANTAGONISTS |
| CN102675290B (zh) | 2011-03-18 | 2014-11-12 | 山东亨利医药科技有限责任公司 | 含有并环的二氢吡唑类化合物 |
| KR101556318B1 (ko) | 2013-05-15 | 2015-10-01 | 한국과학기술연구원 | 칼슘이온 채널 조절제로서 유효한 6-피라졸일아미도-3-치환된 아자바이사이클로[3.1.0]헥산 유도체 |
| US9371282B2 (en) * | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| WO2016075239A1 (en) | 2014-11-14 | 2016-05-19 | Boehringer Ingelheim International Gmbh | Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (sstr4) agonists |
| KR20170082632A (ko) | 2014-11-14 | 2017-07-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 소마토스타틴 수용체 아형 4 (sstr4) 작용제로서의 모르폴린 및 1,4-옥사제판 아미드 |
-
2022
- 2022-09-13 AR ARP220102484A patent/AR127055A1/es unknown
- 2022-09-13 TW TW111134517A patent/TWI822326B/zh active
- 2022-09-13 TW TW112136333A patent/TW202400577A/zh unknown
- 2022-09-14 US US17/944,429 patent/US11834435B2/en active Active
- 2022-09-14 AU AU2022348561A patent/AU2022348561A1/en active Pending
- 2022-09-14 CN CN202280062405.0A patent/CN117940413A/zh active Pending
- 2022-09-14 CA CA3231451A patent/CA3231451A1/en active Pending
- 2022-09-14 KR KR1020247011858A patent/KR20240056751A/ko active Search and Examination
- 2022-09-14 WO PCT/US2022/076401 patent/WO2023044326A1/en active Application Filing
- 2022-09-14 PE PE2024000415A patent/PE20240885A1/es unknown
- 2022-09-14 IL IL311251A patent/IL311251A/en unknown
-
2023
- 2023-08-07 US US18/366,218 patent/US20240067628A1/en active Pending
-
2024
- 2024-03-13 CO CONC2024/0003038A patent/CO2024003038A2/es unknown
- 2024-03-14 DO DO2024000050A patent/DOP2024000050A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI822326B (zh) | 2023-11-11 |
| CO2024003038A2 (es) | 2024-04-18 |
| AR127055A1 (es) | 2023-12-13 |
| PE20240885A1 (es) | 2024-04-24 |
| TW202400577A (zh) | 2024-01-01 |
| US20230099116A1 (en) | 2023-03-30 |
| CA3231451A1 (en) | 2023-03-23 |
| IL311251A (en) | 2024-05-01 |
| US11834435B2 (en) | 2023-12-05 |
| US20240067628A1 (en) | 2024-02-29 |
| TW202330492A (zh) | 2023-08-01 |
| AU2022348561A1 (en) | 2024-03-14 |
| WO2023044326A1 (en) | 2023-03-23 |
| CN117940413A (zh) | 2024-04-26 |
| KR20240056751A (ko) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202100009A (es) | Métodos para reducir la necesidad de revascu | |
| AR116753A1 (es) | Proceso de preparación de un derivado de pirazolsulfonilamida | |
| UY27619A1 (es) | Ésteres hidroxamato del ácido n-(4-fenil sustituido)- antranílico | |
| NI200600306A (es) | Derivados de sulfamida y sulfamato para el tratamiento de la epilepsia y trastornos relacionados | |
| CR8118A (es) | Aril y heteroaril derivados fusionados como moduladores del metabolismo y la prevencion y tratamiento de trastornos relacionados con el mismo | |
| PE20070541A1 (es) | Compuestos y composiciones que comprenden isoindol-imidas | |
| BRPI0415683A (pt) | inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central | |
| HN2002000319A (es) | Benzamida, heteroarilamida y amidas inversas | |
| AR039716A1 (es) | Secuencias de acidos nucleicos relacionadas con tioesterasas y metodos de uso para la produccion de plantas con composicion de acidos grasos modificada | |
| UY28721A1 (es) | Derivados de sulfonamida para eltratamiento de enfermedades | |
| ECSP056148A (es) | Compuestos inmunosupresores y composiciones | |
| AR084433A1 (es) | Inhibidores de la faah y composiciones farmaceuticas que los contienen | |
| PE20080332A1 (es) | Metodos para mejoramiento de funcion cognitiva | |
| EA200801826A1 (ru) | Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения | |
| UY27618A1 (es) | Ésteres hidroxamato de ácido n-(4-fenil-sustituido)-antranílico | |
| CR7807A (es) | Piperacinil y diacepanil benzamidas y benztioamidas | |
| PA8627001A1 (es) | Compuestos para el tratamiento de enfermedades | |
| Varela et al. | Gibbilimbol analogues as antiparasitic agents—Synthesis and biological activity against Trypanosoma cruzi and Leishmania (L.) infantum | |
| BR0314299A (pt) | Derivados de pirrolidona como inibidores de mao-b | |
| AR109224A2 (es) | Formas de sales cristalinas de un compuesto 8-azabiciclo[3,2,1]octano, composición farmacéutica que las comprende, procesos para prepararlas, compuesto intermediario de síntesis relacionado y su uso para la fabricación de un medicamento | |
| BRPI0410391A (pt) | derivados (2-hidróxi-2-(4-hidróxi-3-hidroximetilfenil)-etilamino)- propilfenila como agonistas beta2 | |
| BRPI0408863A (pt) | composto, composição farmacêutica, método para tratar doenças, e, uso de um composto. | |
| BR0314195A (pt) | Derivados de piridina substituìda como agentes antitumorais | |
| EP1333022A3 (fr) | Compositions comprenant des dérivés du cyclopentane, et utilisation pour favoriser la desquamation | |
| GT200600397A (es) | Formulas topicas conteniendo o-desmetil venlafaxina (odv) o sus sales |